Search
for
Sort by
Research 30 of 108
- PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice
- PCPT Results Could Affect Trial on Testosterone Replacement
- Étude PCPT : les biais attendus et leur gestion
- L’étude PCPT
- L'etude PCPT : regards d'un urologue intéressé
- 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
- Pertinence d’une chimioprévention à partir de l’étude PCPT
- Level-1 Data From the REDUCE Study and the PCPT Data
- Le point de vue du pathologiste concernant l’étude PCPT
- 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
- Alcohol and Prostate Cancer: Time to Draw Conclusions
- Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
- A cornerstone of hematological science
- Urological Oncology: Prostate Cancer
- Gleason grading controversies: what the chemoprevention trials have taught us
- Editorial Comment
- Finasteride en el año 2006
- Finasteride: Middle-Age Cure-All for Alopecia and Benign Prostatic Hyperplasia?–Reply–II
- Biomarker-based methods for determining noncompliance in a prevention trial
- Slow progress in prostate cancer
- Editorial comment 1
- Adherence with protocol medication use and mortality from unrelated causes in a prevention trial
- THERAPEUTIC HOTLINE: Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
- Finasteride Doesn't Shorten Survival in Long-term Study
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- The clinical applications of five-alpha reductase inhibitors.
- Male alopecia, finasteride, and cancer risk
- Reply by the authors
- Moving Chemoprevention Forward into the Most Promising Areas of Study
- The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention